Please login to the form below

Not currently logged in

AZ takes Chi-Med’s kidney cancer drug into phase III

SAVOIR trial will compare Chi-Med’s savolitinib to Pfizer’s Sutent


AstraZeneca (AZ) has started phase III trials of savolitinib, a drug for a rare form of kidney cancer, in partnership with its original developer Hutchison China MediTech (Chi-Med).

The start of the late-stage trials programme triggers a $5m payment from AZ to the Hong Kong-based biotech company, which is listed on the London Stock Exchange, and marks a key milestone in Chi-Med's efforts to develop a range of oral cancer drugs for international markets. AZ licensed rights to savolitinib in 2011.

The SAVOIR trial will compare savolitinib to Pfizer's marketed RCC drug Sutent (sunitinib) in patients with papillary renal cell carcinoma (PRCC) whose tumours are driven by the c-MET cancer-associated mutation, and is billed as the first to test a molecularly-targeted therapy in PRCC. It is intended to support marketing applications for savolitinib in Europe and the US, according to Chi-Med.

More than 80% of RCC tumours originate in clear cells - found in the epithelial cells lining the kidney. PRCC is the most common form of non-clear cell RCC, accounting for around 10-15% of all cases and the c-MET pathway is thought to be an important driver in most cases of PRCC.

Savolitinib is at the forefront of an effort to develop more effective treatment strategies that are moving towards a "precision medicine" approach to PRCC.

Phase II results with savolitinib in 109 PRCC patients have just been published in the Journal of Clinical Oncology, with around 40% those recruited having c-MET-driven tumours, 40% c-MET-independent and 20% with unknown c-MET status.

Response to the drug was strongly associated with c-MET status, with median progression-free survival (PFS) more than six months in c-MET-driven disease versus 1.4 months in c-MET-independent disease.

"Based on the results of our phase II study, we believe savolitinib has the potential to bring meaningful clinical benefit to patients with c-MET-driven PRCC," said Christian Hogg, Chi-Med's chief executive. He noted that the company has developed a companion diagnostic that will be used to select patients for its phase III programme.

Meanwhile, savolitinib is also being tested in combination with AZ's pair of immuno-oncology drugs - recently-approved PD-L1 inhibitor Imfinzi (durvalumab) and CTLA4 inhibitor tremelimumab - in the CALYPSO trial involving a broader population of patients with metastatic RCC.

The two partners have various other combination studies ongoing, including one pairing savolitinib with AZ's third-generation EGFR inhibitor Tagrisso (osimertinib) in patients with EGFR-positive advanced lung cancer.

Article by
Phil Taylor

29th June 2017

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...